[Skip to Navigation]
June 4, 2020

Shared and Usable Data From Phase 1 Oncology Trials—An Unmet Need

Author Affiliations
  • 1Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts
JAMA Oncol. 2020;6(7):980-981. doi:10.1001/jamaoncol.2020.0144

Data sharing in clinical trials is increasingly recognized as fundamental to strengthening therapeutic research.1 Several funding organizations have developed data sharing policies for clinical studies, and the International Committee of Medical Journal Editors (http://www.icmje.org) has promoted the diffusion of study results and patient-level data from clinical trials. JAMA Oncology and the other JAMA Network journals require authors of randomized clinical trials to include data sharing statements with their published articles.2 In recent years, sharing of patient-level data has improved with new platforms such as ClinicalTrials.gov, Project Data Sphere, Clinical Study Data Request, and Vivli.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words